Associate Professor, Medicine, Indiana University School of Medicine
Hematology
Dr. Nasser H. Hanna, MD
|
|
Give Review
Nasser Hanna is an expert in the field of Hematology. He studied medicine at Indiana University School of Medicine. Indiana University School of Medicine is ranked 45/47 in Research/PrimaryCare. Doctor Nasser H. Hanna, MD is a published physician as well. He has 91 publications published. The latest was: Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin''s B-cell lymphoma. He accepts all Medicare patients.
Publications
- Prognostic factors in patients with poor risk germ cell Tumors: a retrospective analysis of the Indiana University experience from 1990-2014.
- Phase II study of fosaprepitant + 5HT3 receptor antagonist + dexamethasone in patients with germ cell Tumors undergoing 5-day cisplatin-based chemotherapy: a Hoosier C...
- Electronic nicotine delivery systems: a policy statement from the american association for Cancer research and the american society of clinical oncology.
- Acceptability and Feasibility of a Meaning-Based Intervention for Patients With Advanced Cancer and Their Spouses: A Pilot Study.
- Three-arm, randomized, phase 2 study of carboplatin and paclitaxel in combination with cetuximab, cixutumumab, or both for advanced nonsmall cell lung Cancer (NSCLC) p...
- A randomized phase 2 study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small cell lung Cancer (NSCLC).
- Coping with physical and psychological symptoms: a qualitative study of advanced lung Cancer patients and their family caregivers.
- Phase I Study of Amrubicin and Cyclophosphamide in Patients With Advanced Solid Organ Malignancies: HOG LUN 07-130.
- Testicular Cancer: A Reflection on 50 Years of Discovery.
- Targeting multiple angiogenic pathways simultaneously: experience with nintedanib in non-small-cell lung Cancer.
- Nintedanib for the treatment of non-small-cell lung Cancer.
- Barriers to mental health service use and preferences for addressing emotional concerns among lung Cancer patients.
- A Phase II Study with Cetuximab and Radiation Therapy for Patients with Surgically Resectable Esophageal and GE Junction Carcinomas: Hoosier Oncology Group G05-92.
- Support service use and interest in support services among lung Cancer patients.
- Support service use and interest in support services among distressed family caregivers of lung Cancer patients.
- Addressing Tobacco Use in Patients With Cancer: A Survey of American Society of Clinical Oncology Members.
- Helping Patients Quit Tobacco: ASCO's Efforts to Help Oncology Care Specialists.
- Tobacco Cessation and Control a Decade Later: American Society of Clinical Oncology Policy Statement Update.
- Distressed family caregivers of lung Cancer patients: an examination of psychosocial and practical challenges.
- Erlotinib and Bevacizumab in Newly Diagnosed Performance Status 2 or Elderly Patients With Nonsquamous Non-Small-Cell Lung Cancer, a Phase II Study of the Hoosier Onco...
- Economic and social changes among distressed family caregivers of lung Cancer patients.
- Updated survival and outcomes for older adults with inoperable stage III non-small-cell lung Cancer treated with cisplatin, etoposide, and concurrent chest radiation w...
- Sunitinib Plus Paclitaxel in Patients with Advanced Esophageal Cancer: A Phase II Study from the Hoosier Oncology Groupe.
- Phase 2 Trial of Linifanib (ABT-869) in Patients with Advanced Non-small Cell Lung Cancer.
- Dimensional versus categorical use of the PHQ-9 depression scale among persons with non-small-cell lung Cancer: a pilot study including quality-of-life comparisons.
- The role of maintenance chemotherapy in advanced nonsmall cell lung Cancer.
- Is"chemobrain" a transient state? A prospective pilot study among persons with non-small cell lung Cancer.
- Summary statement novel agents in the treatment of lung Cancer: Fifth Cambridge Conference assessing opportunities for combination therapy.
- Prognostic factors in stage III non-small-cell lung Cancer.
- Postoperative chemotherapy for n2 non-small-cell lung Cancer: conclusions are not black and white, but gray.
- Salvage therapy in patients with advanced non-small cell lung Cancer.
- Chemotherapy and radiotherapy in the treatment of resectable non-small-cell lung Cancer.
- Differential effects of gefitinib and cetuximab on non-small-cell lung Cancers bearing epidermal growth factor receptor mutations.
- Long-term survival in a patient with stage IV non-small-cell Lung carcinoma after bone metastasectomy.
- Antimetabolites in the management of non-small cell lung Cancer.
- Second-line chemotherapy for non-small-cell lung Cancer: recent data with pemetrexed.
- Small-cell lung Cancer: state of the art.
- Phase I trial of topotecan plus vinorelbine with/without filgrastim (G-CSF) in patients with refractory Malignancies.
- The value of platinum compounds in non-small-cell lung Cancer.
- Primary choriocarcinoma of the bladder with the detection of isochromosome 12p.
- Advanced non-small cell lung Cancer: the role of maintenance therapy.
- A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study.
- Phase II study of BBR 3464 as treatment in patients with sensitive or refractory small cell lung Cancer.
- Pemetrexed (Alimta): improving outcomes in Malignant pleural mesothelioma.
- Treatment of small cell lung Cancer.
- Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung Cancer previously treated with chemotherapy.
- Phase I trial of carboplatin and paclitaxel with escalating doses of oral topotecan in patients with solid Tumors.
- Phase II trial of cetuximab in patients with previously treated non-small-cell lung Cancer.
- Paclitaxel plus bevacizumab in patients with chemosensitive relapsed small cell lung Cancer: a safety, feasibility, and efficacy study from the Hoosier Oncology Group.
- Pemetrexed plus cetuximab in patients with recurrent non-small cell lung Cancer (NSCLC): a phase I/II study from the Hoosier Oncology Group.
- Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-Small-cell lu...
- Pemetrexed in second line and beyond small cell lung Cancer: a Hoosier Oncology Group phase II study.
- Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung Cancer.
- Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients w...
- Gefitinib plus celecoxib in chemotherapy-naïve patients with stage IIIB/IV non-small cell lung Cancer: a phase II study from the Hoosier Oncology Group.
- Second-line treatment of advanced non-small cell lung Cancer.
- A phase II study of weekly gemcitabine and paclitaxel in patients with previously untreated stage IIIb and IV non-small cell lung Cancer.
- Recombinant human angiostatin (rhAngiostatin) in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung Cancer: a phase II study fro...
- Maintenance daily oral etoposide versus no further therapy following induction chemotherapy with etoposide plus ifosfamide plus cisplatin in extensive small-cell Lung ...
- A phase II study of methylphenidate for the treatment of fatigue.
- Survival outcomes of resected patients who demonstrate a pathologic complete response after neoadjuvant chemoradiation therapy for locally advanced esophageal Cancer.
- Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung Cancer.
- Large cell carcinoma of the Lung mimicking a germ cell tumor: the potential value of chromosome analysis.
- Gefitinib in patients with chemo-sensitive and chemo-refractory relapsed small cell Cancers: a Hoosier Oncology Group phase II trial.
- Second-line treatment of non-small cell lung Cancer: big targets, small progress; small targets, big progress?
- Advances in the treatment of second-line non-small-cell lung Cancer.
- Dose-volume analysis of radiation pneumonitis in non-small-cell lung Cancer patients treated with concurrent cisplatinum and etoposide with or without consolidation do...
- A retrospective analysis comparing patients 70 years or older to patients younger than 70 years with non-small-cell lung Cancer treated with surgery at Indiana univers...
- Cetuximab in non-small cell lung Cancer.
- Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung Cancer.
- Responsiveness to cetuximab without mutations in EGFR.
- Combined chemoradiotherapy in small cell lung Cancer.
- Recent issues in first-line treatment of advanced non-small-cell lung Cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic O...
- Carboplatin plus paclitaxel and sequential radiation followed by consolidation carboplatin and paclitaxel in patients with previously untreated locally advanced NSCLC....
- Etoposide, ifosfamide and cisplatin (VIP) plus concurrent radiation therapy for previously untreated limited small cell lung Cancer (SCLC): a Hoosier Oncology Group (H...
- High-dose carboplatin with etoposide in patients with recurrent thymoma: the Indiana University experience.
- Randomized, double-blinded, multicenter, phase II study of pemetrexed, carboplatin, and bevacizumab with enzastaurin or placebo in chemonaïve patients with stage IIIB/...
- Cisplatin, fluorouracil, celecoxib, and RT in resectable esophageal Cancer: preliminary results.
- The impact of induction chemotherapy on the outcome of second-line therapy with pemetrexed or docetaxel in patients with advanced non-small-cell lung Cancer.
- Phase I open-label study of continuous treatment with BIBF 1120, a triple angiokinase inhibitor, and pemetrexed in pretreated non-small cell lung Cancer patients.
- The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies.
- Screening studies for fatigue and laboratory correlates in Cancer patients undergoing treatment.
- Diagnostic and therapeutic quandaries in a patient with a germ cell tumor.
- Unlocking the biological clues of lung Cancer.
- Brain metastases as the primary site of relapse in two randomized phase III pemetrexed trials in advanced non-small-cell lung Cancer.
- Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface Malignancies of colonic origin: a consensus statement. Soci...
- Prognostic significance of postchemoradiation stage following preoperative chemotherapy and radiation for advanced/recurrent rectal Cancers.
- Induction of T-cell immunity against Ras oncoproteins by soluble protein or Ras-expressing Escherichia coli.
- Targeted anti-Cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin''s B-cell lymphoma.
- Clinical results of cytoreduction and HIPEC for Malignant peritoneal mesothelioma.
Schools
University Of MissouriColumbia School Of Medicine
University Iowa
Ind University Hospital
Procedures Preformed
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anemia
- Brain and Nervous System Cancer (incl. Gliomas, Astrocytoma, Schwannoma, Medulloblastoma, Chordoma)
- View All
Doctors Specialties
- Medical Oncology
- Oncology
- Hematology
Accepted Insurances
- Choice Plus POS II
- Pathway X Bronze Direct CACA IN HIX
- Anthem Blue Cross Blue Shield HMO
- Anthem Blue Cross Blue Shield PPO
- Blue Card PPO
- Blue Cross Blue Shield of Illinois PPO
- CareSource
- CHAMPVA
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Cofinity PPO
- Commercial Insurance Company
- Coventry Health Care
- Emblem Health
- First Health (Coventry Health Care) PPO
- Golden Rule
- HealthSmart
- Choice Care PPO
- Mail Handlers Benefit Plan (MHBP)
- Medical Mutual of Ohio
- Medicare MCR
- Meritain Health
- MultiPlan PPO
- PHCS Network PPO
- Mutual of Omaha
- Pekin Insurance
- Sagamore Plus
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
Education
-
Indiana University School of Medicine -
University of Iowa Hospitals and Clinics -
University of Missouri-Columbia School of Medicine
Drug Facts
| NPI NUMBER | 1316903883 | |
| NPPES Provider LastName | HANNA | |
| NPPES Provider FirstName | NASSER | |
| NPPES Provider ZIPCode | 462025112 | |
| NPPES Provider State | IN | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 537.0 | |
| Distinct Opioid Count | 4.0 | |
| Opioid Claim Count | 128.0 | |
| Percent Opioid Claims | 23.84 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1316903883 |
| Last Name Of The Provider | HANNA |
| First Name Of The Provider | NASSER |
| View All |
Similar Doctors
|
|
Dr. Foluso O. Ademuyiwa, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Indra N. Frank, MD |
|
|
Dr. Manan C. Patel, MD |
|
|
Dr. Matthew D. Carr, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stephanie A. Wagner, MD
This Doctor is OpenDoctor Recommended.
|